The market for age-related macular degeneration (AMD) drugs could grow at a compound annual growth rate of 8.9% and reach $11.5bn by 2026, according to a report.

Conducted by Global Data, the report covers the seven major AMD markets: the US, France, Germany, Italy, Spain, the UK and Japan.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The launch of new drugs and the increasing number of AMD cases in elderly people are predicted to be the driving factors for the anticipated growth of the market, which was worth an estimated $4.9bn in 2016.

Three new therapies are expected to be introduced to address geographic atrophy (GA), the late-stage dry age-related macular degeneration (dAMD), and three late-stage pipeline products for wet AMD (wAMD).

“The launch of new drugs and the increasing number of AMD cases in elderly people are predicted to be the driving factors for the anticipated growth.”

As dAMD currently lacks prescription medications, new drugs targeting this condition will play a major role in bolstering the market. These drugs include Apellis’ APL-2, Ophthotech’s Zimura and Allergan’s Brimo DDS.

APL-2 has already demonstrated positive profile in Phase IIa clinical trialS for GA and results from a  Phase III trial are expected to get the drug blockbuster status by 2025.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Global Data healthcare analyst Edit Kovalcsik believes that the losses incurred by Novartis over Eylea, an injection treatment for macular degeneration, will be counterbalanced with the launch of its brolucizumab drug, helping the company regain AMD market dominance.

“Once more efficacy and safety data accumulates and physicians become more accustomed to the use of brolucizumab, its advantage of less frequent dosing will allow it to claim an increasing share and become a first-line therapy if reimburse” Kovalcsik added.

Set to attain blockbuster status by 2021, brolucizumab is predicted to become the highest selling AMD drug by 2026, with global sales of $4.1bn.